将孕妇和哺乳期女性纳入研究:努力与倡议
本文概述了孕妇和哺乳期女性因历史原因被排除在临床试验之外,导致大多数获批药物缺乏妊娠期安全性和有效性信息。作者讨论了鼓励或要求纳入这些人群的政策考虑,并提出了利用药物计量学工具和创新临床试验设计等实用策略,以增加对妊娠和哺乳期用药的药代动力学和药效学理解。
要点
- 孕妇和哺乳期女性长期被排除在临床试验之外,导致用药信息缺乏。
- 政策上鼓励或要求纳入孕妇和哺乳期女性可弥补信息缺口。
- 药物计量学工具和创新试验设计可提升妊娠哺乳期用药知识。
核心结论
- 孕妇和哺乳期女性因历史排除而成为治疗孤儿,缺乏妊娠期用药安全性和有效性数据。
- 政策鼓励或要求纳入这些人群,结合药物计量学工具和创新试验设计,可改善妊娠和哺乳期用药的药代动力学和药效学理解。
研究设计与样本
- 本文为综述,提供了妊娠和哺乳期用药的药物流行病学广泛概述,并为监管机构、学术和工业界研究人员提供建议。
主要发现
- 大多数获批药物的标签不提供妊娠期安全性和有效性信息。
- 缺乏数据主要归因于二乙烯雌酚和沙利度胺时代后根深蒂固的伦理法律挑战。
- 妊娠在临床试验环境中主要被视为药物警戒视角。
临床怎么用
- 鼓励或要求将孕妇或哺乳期女性纳入临床试验的政策考虑。
- 采用药物计量学工具和引入创新临床试验设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pregnant and breastfeeding women have been rendered therapeutic orphans as they have been historically excluded from clinical trials. Labelling for most approved drugs does not provide information about safety and efficacy during pregnancy. This lack of data is mainly due to ethico-legal challenges that have remained entrenched in the post-diethylstilbestrol and thalidomide era, and that have led to pregnancy being viewed in the clinical trial setting primarily through a pharmacovigilance lens. Policy considerations that encourage and/or require the inclusion of pregnant or lactating women in clinical trials may address the current lack of available information. However, there are additional pragmatic strategies, such the employment of pharmacometric tools and the introduction of innovative clinical trial designs, which could improve knowledge about the safety and efficacy of medication use during pregnancy and lactation. This paper provides a broad overview of the pharmacoepidemiology of drugs used during pregnancy and lactation, and offers recommendations for regulators and researchers in academia and industry to increase the available pharmacokinetic and -dynamic understanding of medication use in pregnancy.
引用
- Illamola SM, Bucci-Rechtweg C, Costantine MM, et al. Inclusion of pregnant and breastfeeding women in research - efforts and initiatives. Br J Clin Pharmacol. 2017. PMID: 28925019. doi:10.1111/bcp.13438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。